Show simple item record

dc.contributor.authorKu, E.
dc.contributor.authorLee, B.J.
dc.contributor.authorWei, J.
dc.date.accessioned2019-08-05T17:00:33Z
dc.date.available2019-08-05T17:00:33Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85063011514&doi=10.1053%2fj.ajkd.2018.12.044&partnerID=40&md5=a3c7b4f838bcd0030eaf4f4360df3e99
dc.identifier.urihttp://hdl.handle.net/10713/10241
dc.description.abstractHypertension and chronic kidney disease (CKD) are closely interlinked pathophysiologic states, such that sustained hypertension can lead to worsening kidney function and progressive decline in kidney function can conversely lead to worsening blood pressure (BP) control. The pathophysiology of hypertension in CKD is complex and is a sequela of multiple factors, including reduced nephron mass, increased sodium retention and extracellular volume expansion, sympathetic nervous system overactivity, activation of hormones including the renin-angiotensin-aldosterone system, and endothelial dysfunction. Currently, the treatment target for patients with CKD is a clinic systolic BP < 130 mm Hg. The main approaches to the management of hypertension in CKD include dietary salt restriction, initiation of treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and diuretic therapy. Uncontrolled hypertension can lead to significant cardiovascular morbidity and mortality and accelerate progression to end-stage kidney disease. Although intensive BP control has not been shown in clinical trials to slow the progression of CKD, intensive BP control reduces the risk for adverse cardiovascular outcomes and mortality in the CKD population.en_US
dc.description.sponsorshipDr Ku is funded by NHLBI HL131023.en_US
dc.description.urihttps://doi.org/10.1053/j.ajkd.2018.12.044en_US
dc.language.isoen-USen_US
dc.publisherW.B. Saundersen_US
dc.relation.ispartofAmerican Journal of Kidney Diseases
dc.subjectambulatory blood pressure monitoring (ABPM)en_US
dc.subjectantihypertensive agentsen_US
dc.subjectblood pressure (BP)en_US
dc.subjectBP controlen_US
dc.subjectcardiovascular outcomesen_US
dc.subjectchronic kidney disease (CKD)en_US
dc.subjectHypertensionen_US
dc.subjectrenin-angiotensin system (RAS)en_US
dc.subjectreviewen_US
dc.titleHypertension in CKD: Core Curriculum 2019en_US
dc.typearticleen_US
dc.identifier.doi10.1053/j.ajkd.2018.12.044
dc.identifier.pmid30898362


This item appears in the following Collection(s)

Show simple item record